Atrial natriuretic peptide-mediated inhibition of microcirculatory endothelial Ca2+ and permeability response to histamine involves cGMP-dependent protein kinase i and TRPC6 channels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 9, 2013, Pages 2121-2129

  Chen, Wen ^a   Oberwinkler, Heike ^a   Werner, Franziska ^a   Ganer, Birgit ^a   Nakagawa, Hitoshi ^a   Feil, Robert ^b   Hofmann, Franz ^c   Schlossmann, Jens ^d   Dietrich, Alexander ^e   Gudermann, Thomas ^e   Nishida, Motohiro ^f   Del Galdo, Sabrina ^g   Wieland, Thomas ^g   Kuhn, Michaela ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f KYUSHU UNIVERSITY   (Japan)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

atrial natriuretic factor; cyclic GMP; cyclic GMP dependent protein kinase I; endothelial cells; guanylyl cyclase A; TRPC6 channel

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; HISTAMINE; HYPERFORIN; SILDENAFIL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INACTIVATION; MICROCIRCULATION; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR POTENTIAL; VENULE;

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE I; ENDOTHELIAL CELLS; GUANYLYL CYCLASE A; TRPC6 CHANNEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATRIAL NATRIURETIC FACTOR; CALCIUM; CALCIUM CHANNEL BLOCKERS; CAPILLARY PERMEABILITY; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HEK293 CELLS; HISTAMINE; HISTAMINE ANTAGONISTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAST CELLS; MICE; MICE, KNOCKOUT; MICROVESSELS; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TRPC CATION CHANNELS;

EID: 84883291942     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.001974     Document Type: Article

References (42)

1. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res. 2003;93:700-709. (Pubitemid 37288664)
2. Kuhn M. Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol. 2012;166:522-531.
3. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666-1674. (Pubitemid 40814676)
4. Curry FR, Rygh CB, Karlsen T, Wiig H, Adamson RH, Clark JF, Lin YC, Gassner B, Thorsen F, Moen I, Tenstad O, Kuhn M, Reed RK. Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume. J Physiol. 2010;588(pt 2):325-339.
5. Chen W, Gassner B, Börner S, Nikolaev VO, Schlegel N, Waschke J, Steinbronn N, Strasser R, Kuhn M. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res. 2012;93:141-151.
6. Curry FR. Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume. J Clin Invest. 2005;115:1458-1461.
7. Birukova AA, Xing J, Fu P, Yakubov B, Dubrovskyi O, Fortune JA, Klibanov AM, Birukov KG. Atrial natriuretic peptide attenuates LPSinduced lung vascular leak: role of PAK1. Am J Physiol Lung Cell Mol Physiol. 2010;299:L652-L663.
8. Birukova AA, Zagranichnaya T, Alekseeva E, Bokoch GM, Birukov KG. Epac/Rap and PKA are novel mechanisms of ANP-induced Racmediated pulmonary endothelial barrier protection. J Cell Physiol. 2008;215:715-724. (Pubitemid 351632693)
9. Wei XN, Han BC, Zhang JX, Liu XH, Tan CY, Jiang YY, Low BC, Tidor B, Chen YZ. An integrated mathematical model of thrombin-, histamineand VEGF-mediated signalling in endothelial permeability. BMC Syst Biol. 2011;5:112.
10. Shepherd RK, Duling BR. Use of Ruthenium Red staining to detect mast cell degranulation in vivo. Microcirculation. 1995;2:363-370. (Pubitemid 2621554)
11. Wegener JW, Nawrath H, Wolfsgruber W, Kühbandner S, Werner C, Hofmann F, Feil R. cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res. 2002;90:18-20. (Pubitemid 34074603)
12. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230:230-242. (Pubitemid 32171420)
13. Lutz S, Freichel-Blomquist A, Yang Y, Rümenapp U, Jakobs KH, Schmidt M, Wieland T. The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and RhoA. J Biol Chem. 2005;280:11134-11139. (Pubitemid 40418419)
14. Tas PW, Stössel C, Roewer N. Inhibition of the histamine-induced Ca2+ influx in primary human endothelial cells (HUVEC) by volatile anaesthetics. Eur J Anaesthesiol. 2008;25:976-985.
15. Desch M, Sigl K, Hieke B, Salb K, Kees F, Bernhard D, Jochim A, Spiessberger B, Höcherl K, Feil R, Feil S, Lukowski R, Wegener JW, Hofmann F, Schlossmann J. IRAG determines NO-and ANP-mediated smooth muscle relaxation. Cardiovasc Res. 2010;86:496-505.
16. Tiruppathi C, Minshall RD, Paria BC, Vogel SM, Malik AB. Role of Ca2+ signaling in the regulation of endothelial permeability. Vascul Pharmacol. 2002;39:173-185. (Pubitemid 37490745)
17. Nishida M, Watanabe K, Sato Y, Nakaya M, Kitajima N, Ide T, Inoue R, Kurose H. Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. J Biol Chem. 2010;285:13244-13253.
18. Dietrich A, Mederos Y Schnitzler M, Gollasch M, Gross V, Storch U, Dubrovska G, Obst M, Yildirim E, Salanova B, Kalwa H, Essin K, Pinkenburg O, Luft FC, Gudermann T, Birnbaumer L. Increased vascular smooth muscle contractility in TRPC6-/-mice. Mol Cell Biol. 2005;25:6980-6989. (Pubitemid 41105898)
19. Takahashi S, Lin H, Geshi N, Mori Y, Kawarabayashi Y, Takami N, Mori MX, Honda A, Inoue R. Nitric oxide-cGMP-protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6. J Physiol. 2008;586(pt 17):4209-4223.
20. Samapati R, Yang Y, Yin J, Stoerger C, Arenz C, Dietrich A, Gudermann T, Adam D, Wu S, Freichel M, Flockerzi V, Uhlig S, Kuebler WM. Lung endothelial Ca2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6. Am J Respir Crit Care Med. 2012;185:160-170.
21. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Baeurle J, Liedtke W, Wu S, Kuppe H, Pries AR, Kuebler WM. Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. Circ Res. 2008;102:966-974. (Pubitemid 351591552)
22. Fürst R, Bubik MF, Bihari P, Mayer BA, Khandoga AG, Hoffmann F, Rehberg M, Krombach F, Zahler S, Vollmar AM. Atrial natriuretic peptide protects against histamine-induced endothelial barrier dysfunction in vivo. Mol Pharmacol. 2008;74:1-8. (Pubitemid 351872153)
23. Wiedermann CJ, Niedermühlbichler M, Braunsteiner H, Widermann CJ. Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J Clin Invest. 1992;89:1580-1586.
24. Tsukagoshi H, Shimizu Y, Kawata T, Hisada T, Shimizu Y, Iwamae S, Ishizuka T, Iizuka K, Dobashi K, Mori M. Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept. 2001;99:21-29. (Pubitemid 32232124)
25. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang GX, Korth M, Aszódi A, Andersson KE, Krombach F, Mayerhofer A, Ruth P, Fässler R, Hofmann F. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998;17:3045-3051. (Pubitemid 28254377)
26. Schlossmann J, Desch M. IRAG and novel PKG targeting in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2011;301:H672-H682.
27. Dedkova EN, Blatter LA. Nitric oxide inhibits capacitative Ca2+ entry and enhances endoplasmic reticulum Ca2+ uptake in bovine vascular endothelial cells. J Physiol. 2002;539(pt 1):77-91. (Pubitemid 35190098)
28. Weissmann N, Sydykov A, Kalwa H, et al. Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun. 2012;3:649.
29. Pocock TM, Foster RR, Bates DO. Evidence of a role for TRPC channels in VEGF-mediated increased vascular permeability in vivo. Am J Physiol Heart Circ Physiol. 2004;286:H1015-H1026. (Pubitemid 38248617)
30. Blackmore PF. Biphasic effects of nitric oxide on calcium influx in human platelets. Thromb Res. 2011;127:e8-e14.
31. Kinoshita H, Kuwahara K, Nishida M, et al. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Circ Res. 2010;106:1849-1860.
32. Klaiber M, Dankworth B, Kruse M, et al. A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide. Proc Natl Acad Sci USA. 2011;108:18500-18505.
33. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007;101:1084-1095. (Pubitemid 350146434)
34. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008;25:37-44.
35. Balarini CM, Leal MA, Gomes IB, Pereira TM, Gava AL, Meyrelles SS, Vasquez EC. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J Transl Med. 2013;11:3.
36. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
37. Chai OH, Lee YH, Han EH, Kim HT, Lee MS, Song CH. Atrial natriuretic peptide induces rat peritoneal mast cell activation by cGMPindependent and calcium uptake-dependent mechanism. Exp Mol Med. 2000;32:179-186. (Pubitemid 32041696)
38. Szukiewicz D, Maslinska D, Szukiewicz A, Zaczek R, Szewczyk G, Stelmachow J. The dose-dependent release of histamine from placental mast cells after administration of atrial natriuretic peptide. Inflamm Res. 2001;50 (suppl 2):S59-S60. (Pubitemid 32452968)
39. Murray DB, Gardner JD, Levick SP, Brower GL, Morgan LG, Janicki JS. Response of cardiac mast cells to atrial natriuretic peptide. Am J Physiol Heart Circ Physiol. 2007;293:H1216-H1222. (Pubitemid 47254224)
40. Walsh SK, Kane KA, Wainwright CL. Mast cells, peptides and cardioprotection-an unlikely marriage? Auton Autacoid Pharmacol. 2009;29:73-84.
41. Gaboury JP, Niu XF, Kubes P. Nitric oxide inhibits numerous features of mast cell-induced inflammation. Circulation. 1996;93:318-326. (Pubitemid 26031491)
42. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005;69:283-290. (Pubitemid 40410182)